MAH0 Stock Overview
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Mereo BioPharma Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.72 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.87 |
| Beta | 0.80 |
| 1 Month Change | 12.86% |
| 3 Month Change | -16.56% |
| 1 Year Change | 156.60% |
| 3 Year Change | 8.80% |
| 5 Year Change | -29.53% |
| Change since IPO | -33.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAH0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.3% | -1.6% | -0.9% |
| 1Y | 156.6% | -26.8% | 4.5% |
Return vs Industry: MAH0 exceeded the German Biotechs industry which returned -26.8% over the past year.
Return vs Market: MAH0 exceeded the German Market which returned 4.5% over the past year.
Price Volatility
| MAH0 volatility | |
|---|---|
| MAH0 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: MAH0's share price has been volatile over the past 3 months.
Volatility Over Time: MAH0's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Denise Scots-Knight | www.mereobiopharma.com |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
Mereo BioPharma Group plc Fundamentals Summary
| MAH0 fundamental statistics | |
|---|---|
| Market cap | €394.06m |
| Earnings (TTM) | -€24.34m |
| Revenue (TTM) | €9.24m |
41.9x
P/S Ratio-15.9x
P/E RatioIs MAH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAH0 income statement (TTM) | |
|---|---|
| Revenue | US$10.00m |
| Cost of Revenue | US$2.92m |
| Gross Profit | US$7.08m |
| Other Expenses | US$33.42m |
| Earnings | -US$26.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 70.79% |
| Net Profit Margin | -263.41% |
| Debt/Equity Ratio | 10.8% |
How did MAH0 perform over the long term?
See historical performance and comparison